GlassScriptPhysician profile
Dariush Ashrafi
NPI 1659545614
$6,748.03
in general payments reported to CMS, 2019-2025
35 companies · $768 in 2025
The $768 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,978 · 2020: $290 · 2021: $1,106 · 2022: $1,237 · 2023: $962 · 2024: $407 · 2025: $768.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,964 · Travel and Lodging: $147 · Education: $25.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,964.08 |
| Travel and Lodging | $147.36 |
| Education | $25.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,016.05 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Novo Nordisk INC | $537.56 | 2019-2023 | Ozempic, Rybelsus |
| Pfizer INC. | $429.90 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $387.50 | 2019-2024 | Breztri, Farxiga |
| Sanofi-Aventis U.S. LLC | $292.05 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $260.89 | 2019-2023 | Xifaxan |
| Lilly USA, LLC | $251.19 | 2019-2024 | Jardiance, Mounjaro, Trulicity |
| Glaxosmithkline, LLC. | $241.65 | 2019-2023 | Shingrix, Arexvy |
| Novartis Pharmaceuticals Corporation | $198.83 | 2019-2022 | |
| Amgen INC. | $181.42 | 2019-2024 | Repatha, Otezla |
| Biohaven Pharmaceutical Holding Company LTD. | $180.17 | 2022 | |
| Abbott Laboratories | $176.36 | 2021-2025 | Freestyle Libre 3 |
| Biohaven Pharmaceuticals, INC. | $168.52 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $151.30 | 2022-2025 | Rexulti |
| Intuitive Surgical, INC. | $147.36 | 2025 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $140.49 | 2019 | |
| Allergan, INC. | $136.00 | 2019-2020 | |
| Scilex Pharmaceuticals INC. | $117.83 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $107.14 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $90.98 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $84.62 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $77.49 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $65.42 | 2019 | |
| Exact Sciences Corporation | $45.71 | 2025 | Cologuard Collection Kit |
| Xeris Pharmaceuticals, INC. | $43.91 | 2025 | Gvoke Hypopen |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $37.91 | 2022-2025 | Caplyta |
| Ardelyx, INC. | $30.84 | 2025 | Ibsrela |
| Valeritas, INC. | $29.41 | 2019 | |
| Bausch Health US, LLC | $20.04 | 2019 | |
| Ironwood Pharmaceuticals, INC | $18.89 | 2020 | |
| Dexcom, INC. | $17.88 | 2023 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $16.68 | 2024 | Veozah |
| Kowa Pharmaceuticals America, INC. | $16.55 | 2019 | |
| Corium, LLC | $15.39 | 2023 | Adlarity |
| Sanofi Pasteur INC. | $14.10 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dariush Ashrafi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.